Project Grant R43CA302286
Award Date
6/19/25
Completion Date
4/30/26
Dollars Obligated
$353K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $427,095 to Northeastern University to develop a novel microfluidic droplet-based platform (MDP) technology. The MDP will generate and analyze a 3D biomimetic multicellular immunogenic tumor model to: Establish multiple levels of hypoxia within the same tumor-chip for parallel processing. Investigate spatiotemporal interaction between the...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Biology Research program (CFDA 93.396), provides $404,994 to Aperture Bio, Inc. to determine the feasibility of using their platform for pre-clinical applications in drug development, cell therapy manufacturing, regenerative medicine, and oncology research. The goal is to evaluate Aperture Bio's conjugation and quenching technologies, which can stain and quantify cellular perturbations in live cells...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $674,275 in funding to Marker Therapeutics Inc., a small disadvantaged biotechnology company, to conduct a Phase 1 clinical study evaluating the safety and efficacy of their MT-601 multi-tumor associated antigen-specific T-cell therapy in patients with metastatic pancreatic cancer. The study aims to assess the clinical outcomes of combining MT-601 with frontline FOLFIRINOX chemotherapy,...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a novel approach to detect and report on the expression of multiple cytokine genes simultaneously in tissues. The $234,919 award to Yale University, to be completed by August 31, 2027, will combine CRISPR-mediated transcriptional activation with genetically-encoded fluorescent reporters to enable the dynamic, high-sensitivity and multiplexed monitoring of cytokine...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is providing $748,337 to Pyrojas Inc. to develop an innovative "Pyrotimer" CAR-T cell therapy. The goal is to create a more potent and persistent CAR-T cell treatment that can overcome the immunosuppressive tumor microenvironment, particularly by inhibiting transforming growth factor-beta (TGF-β). The research plan involves extensive in vitro and in vivo...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $419,133.00 to the Massachusetts Institute of Technology (MIT) to develop an "ex vivo tumor biosensor" technology called AscitesPredict. The goal is to enable real-time evaluation of therapeutic sensitivities and cell identities from patient ascites (fluid accumulation) samples, which can be more readily obtained than traditional tumor biopsies. The...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $399,958 to Mabswitch Inc., a minority-owned small business, to assess the feasibility of regulating the activation, effector functions, and cytokine release of chimeric antigen receptor (CAR) T-cell therapies. The project aims to develop a "switchable affinity CAR" (SAEFCAR) that can be controlled by an exogenously administered ligand, potentially mitigating the toxicity...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $626,534 in funding to The Medical University of South Carolina to conduct research aimed at understanding how transient endoplasmic reticulum (ER) stress can enhance the anti-tumor function of T cells. The 5-year project, starting on December 1, 2024, will investigate the mechanisms by which ER stress-induced autophagy can improve mitochondrial function, metabolic programming, and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Assayquant Technologies, Inc. provides $1,093,104 to develop and commercialize a suite of biosensor peptides for the quantitative, high-throughput measurement of oncogenic protein kinases in cell and tissue samples. The key products to be developed and validated under this 2-year award include: Lysate-compatible sensor peptides for measuring activity of mitogen-activated protein kinases (MAPKs)...